- Home
- GCV vs GNLX Comparison
GCV vs GNLX Comparison
Compare GCV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCV | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.5M | 110.4M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GCV | GNLX |
|---|---|---|
| Price | $4.07 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.83 |
| AVG Volume (30 Days) | 49.8K | ★ 218.5K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $2.29 |
| 52 Week High | $4.80 | $8.54 |
Technical Indicators
Market Signals| Indicator | GCV | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 26.43 | 45.11 |
| Support Level | N/A | $2.32 |
| Resistance Level | $4.57 | $2.93 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 11.76 | 26.08 |
Price Performance
Historical ComparisonAbout GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive, and others. All the operation of the group is operated through the regions of the United States.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.